{"id":"NCT00065468","sponsor":"Pfizer","briefTitle":"Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma","officialTitle":"A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-07","primaryCompletion":"2006-06","completion":"2011-03","firstPosted":"2003-07-25","resultsPosted":"2012-10-25","lastUpdate":"2012-10-25"},"enrollment":626,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell","Kidney Neoplasms"],"interventions":[{"type":"DRUG","name":"Interferon Alfa","otherNames":[]},{"type":"DRUG","name":"CCI-779","otherNames":[]},{"type":"DRUG","name":"Interferon Alfa and CCI-779","otherNames":[]}],"arms":[{"label":"A","type":"ACTIVE_COMPARATOR"},{"label":"B","type":"EXPERIMENTAL"},{"label":"C","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \\[Temsirolimus\\], administered intravenously \\[IV\\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \\[IFN alfa\\] subcutaneously \\[SC\\] three times per week \\[TIW\\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline up to Month 80","effectByArm":[{"arm":"Interferon Alfa","deltaMin":7.3,"sd":null},{"arm":"Temsirolimus","deltaMin":10.9,"sd":null},{"arm":"Interferon Alfa and Temsirolimus","deltaMin":8.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0252"},{"comp":"OG000 vs OG002","p":"0.4902"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":153,"countries":["United States","Argentina","Australia","Canada","Czechia","Germany","Greece","Hungary","Italy","Latvia","Lithuania","Mexico","Netherlands","Poland","Russia","Serbia and Montenegro","Serbia","Slovakia","South Africa","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37146227","28410911","27238653","25577718","17538086"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3066K1-304&StudyName=Study%20Evaluating%20Interferon%20And%20CCI-779%20In%20Advanced%20Renal%20Cell%20Carcinoma"]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":200},"commonTop":["ASTHENIA","ANEMIA","FEVER","NAUSEA","ANOREXIA"]}}